Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-29
2008-04-29
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S017400, C514S199000, C514S256000, C514S338000, C514S361000, C530S300000, C530S326000, C530S330000, C424S009100
Reexamination Certificate
active
07365047
ABSTRACT:
This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.
REFERENCES:
patent: 4997950 (1991-03-01), Murphy et al.
patent: 5629305 (1997-05-01), Eek et al.
patent: 5750531 (1998-05-01), Lee et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 6013281 (2000-01-01), Lundberg et al.
patent: 6093738 (2000-07-01), Karimian et al.
PCT Search Report for International Application No. PCT/US00/26992.
Campoli-Richards et al. (1986) “Famotidine Pharmacodynamic and Pharmacokinetic Properties and a Preliminary Review of its Therapeutic Use in Peptic Ulcer Disease and Zollinger-Ellison Syndrome”, Drugs 32: 197-221.
Chin et al. (1986) “Absence of Tachyphylaxis in Gastric Acid Secretion During Pentagastrin Infusion” J. Clin. Pharmacol. 26: 281-285.
Davidson et al. (1973) “Renal Extraction and Excretion of Endogenous Gastrin in the Dog”, Gastroenterology 64: 955-961.
Desanto et al. (1992) “Brain-Gut Peptides and the Renal Hemodynamic Response to an Oral Protein Load: A Study of Gastrin, Bombesin, and Glucagon in Man”, Renal Physiol. Biochem. 15: 53-56.
Deveney et al. (1983) “Cimetidine in the Treatment of Zollinger-Ellison Syndrome”, Amer. J. Surg. 146: 116-123.
Drogden et al. (1978) “Cimetidine: A Review of its Pharmacological Properties and Therapeutic Efficacy in Peptic Ulcer Disease”, Drugs 15: 93-131.
El Munshid et al. (1980) “Importance of the Kidneys for Gastrin Elimination and Gastric Function”, J. Physiol. 299: 157-171.
Hansky (1979) “Effect of Renal Failure on Gastrointestinal Hormones”, World J. Surg. 3: 463-467.
Hartman et al. (1998) “Equipotent Inhibition of Gastric Acid Secretion by Equal Doses of Oral or Intravenous Pantoprazole”, Aliment. Pharmacol. Ther. 12: 1027-1032.
Hirschowitz et al. (1995) “Pharmacological Aspects of Acid Secretion”, Dig. Dis. Sci. 40: 2 (suppl) 3S-23S.
Hostetter (1986) “Human Renal Response to a Meat Meal”, Am J. Physiol 250: F613-F618.
Howard et al. (1985) “Famotidine, a New Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome”, Gastroenterology 88: 1026-1033.
Kes et al. (1993) “Influence of Renal Functional Mass on the Catabolism of Endogenous Gastrin in Humans”, Renal Physiol. Biochem. 16: 268-275.
Lotti and Chang (1989) “A New Potent and Selective Non-Peptide Gastrin Antagonist and Brain Cholectstokinin Receptor (CCK-B) Ligand: L-365,260”, Eur. J. Pharmacol. 162: 273-280.
Mason et al. (1969) “Continuous Intravenous Pentagastrin as a Stimulant of Maximal Gastric Acid Secretion”, Gut, 10: 34-38.
McCarthy (1978) “Report on the United States Experience with Cimetidine in Zollinger-Ellison Syndrome and Other Hypersecretory States”, Gastroenterology 74: 453-458.
Nielsen et al. (1980) “The Effect of Renal Transplantation on Basal Serum Gastrin Concentration”, Acta. Med. Scand. 207: 85-87.
Bonfils et al. (1979) “Cimetidine Treatment of Acute and Chronic Zollinger-Ellison Syndrome”, World J. Surg. 3: 597-604.
Rume et al. (1981) “Abstracts of Papers”, Gastroenterology 80:1265.
Saeed et al. (1989) “Parenteral Antisecretory Drug Therapy in Patients with Zollinger-Ellison Syndrome”, Gastroenterology 96: 1393-1402.
Schjonsby and Willassen (1977) “Renal Extraction of Endogenous Gastrin in Patiens with Normal Renal Function”, Gastroenterology 12: 205-207.
Simon et al. (1990) “Single Intravenous Administration of the H+, K+-ATPase Inhibitor BY 1023/SK&F 96022-Inhibition of Pentagastrin-Stimulated Gastrin Acid Secretion and Pharmacokinetics in Man”, Aliment Pharmacol. Therap. 4: 239-245.
Simon et al. (1990) “Pentagastrin-Stimulated Gastric Acid Secretion and Pharmacokinetics Following Singe and Repeated Intravenous Administration of the Gastric H+, K+-ATPase-Inhibitor Pantoprazole (BY1023/SK&F96022) in Healthy Volunteers”, Z. Gastroenterology 28: 443-447.
Vallot et al. (1983) “Evaluation of Antisecretory Drug Therapy of Zollinger-Ellison Syndrome (ZES) Using 24 Hour pH Monitoring”, Dig. Dis. Sci. 28: 7: 577-584.
Wank et al. (1992) “Brain and Gastrointestinal Cholecystokinin Receptor Family: Structure and Functional Expression”, Proc. Natl. Acad. Sci. USA 89: 8691-8695.
Wormsley et al. (1966) “Effects of a Gastrin-Like Pentapeptide (I.C.I. 50, 123) on Stomach and Pancreas”, Lancet, 1: 993-996.
Fraker et al. (1988) “A Prospective Study of Perioperative and Postoperative Control of Acid Hypersecretion in Patients with Zollinger-Ellison Syndrome Undergoing Gastrinoma Resection”, Surgery 104: 6: 1054-1063.
de Graef and Woussen-Cole (1986) “Influence of the Stimulation State of the Parietal Cells on the Inhibitory Effect of Omeprazole on Gastric Acid Secretion in Dogs”, Gastroenterology 9;: 333-337.
Kromer et al. (2000) “Animal Pharmacology of Reversible Antagonism of the Gastric Acid Pump, Compared to Standard Antisecretory Principles” Pharmacology 60: 179-187.
Richardson et al. (1998) Proton Pump Inhibitors: Pharmacology and Rationale for use in Gastrointestinal Disorders Drugs 56 (3) 307-335.
Hunter Tom
Kam Chih-Min
The Regents of the University of California
Weaver Austin Villeneuve & Sampson LLP
LandOfFree
Use of pentagastrin to inhibit gastric acid secretion or as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of pentagastrin to inhibit gastric acid secretion or as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pentagastrin to inhibit gastric acid secretion or as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2755543